BRD4-mediated repression of p53 is a target for combination therapy in AML

MDM2 and BET inhibitors have shown efficacy in AML treatment. Here, the authors show that the two compounds can synergize through both p53 protein stabilization and inhibition of BRD4-mediated repression of p53 target genes.

Guardado en:

Detalles Bibliográficos
Autores principales:	Anne-Louise Latif, Ashley Newcombe, Sha Li, Kathryn Gilroy, Neil A. Robertson, Xue Lei, Helen J. S. Stewart, John Cole, Maria Terradas Terradas, Loveena Rishi, Lynn McGarry, Claire McKeeve, Claire Reid, William Clark, Joana Campos, Kristina Kirschner, Andrew Davis, Jonathan Lopez, Jun-ichi Sakamaki, Jennifer P. Morton, Kevin M. Ryan, Stephen W. G. Tait, Sheela A. Abraham, Tessa Holyoake, Brian Higgins, Xu Huang, Karen Blyth, Mhairi Copland, Timothy J. T. Chevassut, Karen Keeshan, Peter D. Adams
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/4058dbf2924543a399c2f17c8fd2a6ad
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4058dbf2924543a399c2f17c8fd2a6ad
record_format	dspace
spelling	oai:doaj.org-article:4058dbf2924543a399c2f17c8fd2a6ad2021-12-02T14:01:14ZBRD4-mediated repression of p53 is a target for combination therapy in AML10.1038/s41467-020-20378-82041-1723https://doaj.org/article/4058dbf2924543a399c2f17c8fd2a6ad2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-20378-8https://doaj.org/toc/2041-1723MDM2 and BET inhibitors have shown efficacy in AML treatment. Here, the authors show that the two compounds can synergize through both p53 protein stabilization and inhibition of BRD4-mediated repression of p53 target genes.Anne-Louise LatifAshley NewcombeSha LiKathryn GilroyNeil A. RobertsonXue LeiHelen J. S. StewartJohn ColeMaria Terradas TerradasLoveena RishiLynn McGarryClaire McKeeveClaire ReidWilliam ClarkJoana CamposKristina KirschnerAndrew DavisJonathan LopezJun-ichi SakamakiJennifer P. MortonKevin M. RyanStephen W. G. TaitSheela A. AbrahamTessa HolyoakeBrian HigginsXu HuangKaren BlythMhairi CoplandTimothy J. T. ChevassutKaren KeeshanPeter D. AdamsNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Anne-Louise Latif Ashley Newcombe Sha Li Kathryn Gilroy Neil A. Robertson Xue Lei Helen J. S. Stewart John Cole Maria Terradas Terradas Loveena Rishi Lynn McGarry Claire McKeeve Claire Reid William Clark Joana Campos Kristina Kirschner Andrew Davis Jonathan Lopez Jun-ichi Sakamaki Jennifer P. Morton Kevin M. Ryan Stephen W. G. Tait Sheela A. Abraham Tessa Holyoake Brian Higgins Xu Huang Karen Blyth Mhairi Copland Timothy J. T. Chevassut Karen Keeshan Peter D. Adams BRD4-mediated repression of p53 is a target for combination therapy in AML
description	MDM2 and BET inhibitors have shown efficacy in AML treatment. Here, the authors show that the two compounds can synergize through both p53 protein stabilization and inhibition of BRD4-mediated repression of p53 target genes.
format	article
author	Anne-Louise Latif Ashley Newcombe Sha Li Kathryn Gilroy Neil A. Robertson Xue Lei Helen J. S. Stewart John Cole Maria Terradas Terradas Loveena Rishi Lynn McGarry Claire McKeeve Claire Reid William Clark Joana Campos Kristina Kirschner Andrew Davis Jonathan Lopez Jun-ichi Sakamaki Jennifer P. Morton Kevin M. Ryan Stephen W. G. Tait Sheela A. Abraham Tessa Holyoake Brian Higgins Xu Huang Karen Blyth Mhairi Copland Timothy J. T. Chevassut Karen Keeshan Peter D. Adams
author_facet	Anne-Louise Latif Ashley Newcombe Sha Li Kathryn Gilroy Neil A. Robertson Xue Lei Helen J. S. Stewart John Cole Maria Terradas Terradas Loveena Rishi Lynn McGarry Claire McKeeve Claire Reid William Clark Joana Campos Kristina Kirschner Andrew Davis Jonathan Lopez Jun-ichi Sakamaki Jennifer P. Morton Kevin M. Ryan Stephen W. G. Tait Sheela A. Abraham Tessa Holyoake Brian Higgins Xu Huang Karen Blyth Mhairi Copland Timothy J. T. Chevassut Karen Keeshan Peter D. Adams
author_sort	Anne-Louise Latif
title	BRD4-mediated repression of p53 is a target for combination therapy in AML
title_short	BRD4-mediated repression of p53 is a target for combination therapy in AML
title_full	BRD4-mediated repression of p53 is a target for combination therapy in AML
title_fullStr	BRD4-mediated repression of p53 is a target for combination therapy in AML
title_full_unstemmed	BRD4-mediated repression of p53 is a target for combination therapy in AML
title_sort	brd4-mediated repression of p53 is a target for combination therapy in aml
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/4058dbf2924543a399c2f17c8fd2a6ad
work_keys_str_mv	AT annelouiselatif brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT ashleynewcombe brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT shali brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT kathryngilroy brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT neilarobertson brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT xuelei brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT helenjsstewart brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT johncole brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT mariaterradasterradas brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT loveenarishi brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT lynnmcgarry brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT clairemckeeve brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT clairereid brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT williamclark brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT joanacampos brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT kristinakirschner brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT andrewdavis brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT jonathanlopez brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT junichisakamaki brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT jenniferpmorton brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT kevinmryan brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT stephenwgtait brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT sheelaaabraham brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT tessaholyoake brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT brianhiggins brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT xuhuang brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT karenblyth brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT mhairicopland brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT timothyjtchevassut brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT karenkeeshan brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml AT peterdadams brd4mediatedrepressionofp53isatargetforcombinationtherapyinaml
_version_	1718392194026438656

BRD4-mediated repression of p53 is a target for combination therapy in AML

Ejemplares similares